About
DiagnosTear specializes in technology for the diagnosis and treatment of dry eye syndrome. The company is developing an assay designed to facilitate the diagnosis, treatment, and monitoring of dry eye syndrome by examining certain parameters in tear fluid. DiagnosTears TeaRx assay is based on various reagents that create color reactions when coming into contact with tear film, allowing for a semi-quantitative assessment of the parameters that define the syndrome. Information on the parameters assists in the diagnosis of the syndrome and enables a better, more informed selection of treatment and monitoring options. TeaRx enables the monitoring and screening of the condition by examining up to five different varieties of tear fluid. The test is carried out through the use of a simple device that is placed under the lower eyelid to absorb the tear fluid. DiagnosTear is an XLVision Sciences company and a fully owned subsidiary of BioLight.
Funding history · 3 rounds · $4.6M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did DiagnosTear become a public company and on what exchange?
- DiagnosTear became public on the CSE in December 2024 through a reverse merger.
- What is the primary focus of DiagnosTear's technology?
- DiagnosTear specializes in technology for the diagnosis and treatment of dry eye syndrome, developing an assay to examine parameters in tear fluid.
- What is the name of DiagnosTear's main product and what does it do?
- DiagnosTear's main product is the TeaRx assay, which uses reagents to create color reactions with tear film for semi-quantitative assessment of dry eye syndrome parameters. It enables monitoring and screening by examining up to five varieties of tear fluid.
- What was DiagnosTear's most recent funding round and when did it occur?
- DiagnosTear's most recent funding round was a PIPE in November 2025, raising $660,000. For full financing history, refer to startupim.
- Which organizations did DiagnosTear collaborate with for clinical validation of TeaRx(TM) Red Eye in November 2025?
- In November 2025, DiagnosTear initiated a collaboration with LV Prasad Eye Institute for advancing the clinical validation of TeaRx(TM) Red Eye Diagnostic Test.
- What was DiagnosTear's significant market entry development in the UK in February 2026?
- In February 2026, DiagnosTear advanced its UK market entry through a commercial collaboration with Hanson Medical.
- What regulatory approvals did DiagnosTear announce in February 2026?
- In February 2026, DiagnosTear announced regulatory approvals in France and the initiation of a study with AlyaTec for TeaRx(TM) Red Eye.
- What is DiagnosTear's relationship with BioLight?
- DiagnosTear is an XLVision Sciences company and a fully owned subsidiary of BioLight.
- What was the outcome of DiagnosTear's interim clinical results for TeaRx(TM) Red Eye announced in January 2026?
- In January 2026, DiagnosTear announced interim clinical results indicating high efficiency from TeaRx(TM) Red Eye.